Potent broadly reactive neutralising HIV-1 monoclonal antibodies

有效的广泛反应性中和 HIV-1 单克隆抗体

• 批准号: nhmrc : 502617
• 负责人: A/Pr Dale Mcphee
• 金额: $ 30.88万
• 依托单位: St. Vincent's Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2008
• 资助国家: 澳大利亚
• 起止时间: 2008-01-01 至 2010-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/potent-broadly-reactive-monoclonal-antibodies/77831
• 关键词: Potent; broadly; reactive; neutralising; HIV

A successful vaccine prevents infection. For HIV infection all candidate vaccines thus far have failed. From the many HIV-1 infected individuals there are a very small percentage that do not progress to disease. For these infected subjects we hypothesise that their immune responses are much better preserved and hence they will have stronger antibody responses. We have geared up our laboratory to characterise these strong antibodies and use them in making a better HIV-1 vaccine.

一种成功的疫苗可以预防感染。对于艾滋病毒感染，到目前为止，所有候选疫苗都失败了。在许多感染艾滋病毒-1的人中，有很小一部分人没有进展为疾病。对于这些受感染的受试者，我们假设他们的免疫反应保存得更好，因此他们将有更强的抗体反应。我们已经准备好了我们的实验室来表征这些强大的抗体，并将它们用于制造更好的HIV-1疫苗。